Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients
This is a randomized clinical trial to investigate the efficacy of letrozole combined with metronomic oral cyclophosphamide in elderly metastasis breast cancer patients.
Breast Neoplasms|Neoplasm Metastasis
DRUG: Cyclophosphamide 50mg|DRUG: Letrozole 2.5 mg
Progression free survival(PFS) of the subjects, Time from the randomization date to the start of disease progression or subject death from any cause (progression assessed by investigator using Response Evaluation Criteria in Solid Tumors 1.1for elderly metastatic breast cancer subjects)., up to approximately 2 years
Safety of each treatment regimen for the subjects, Assessment based on Adverse Events (AEs) , Serious Adverse Events (SAEs), laboratory abnormalities in subjects ., up to approximately 2 years|Evaluate the quality of life for the subjects in the each treatment regimen, Subjects complete questionnaire in every 8 weeks., up to approximately 2 years|Compare disease control rate for the subjects, Complete response (CR), Partial response (PR), and Stable Disease (SD) more than or equal to 8 weeks., up to approximately 2 years
This is a randomized clinical trial to investigate the efficacy of letrozole combined with metronomic oral cyclophosphamide in elderly metastasis breast cancer patients.